Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider directly owned 27,559 shares in the company, valued at $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Trading Up 0.7%

KROS opened at $11.03 on Friday. The stock’s fifty day simple moving average is $10.71 and its 200 day simple moving average is $11.84. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55. The stock has a market cap of $218.72 million, a PE ratio of -2.98 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities analysts forecast that Keros Therapeutics, Inc. will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on KROS shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Leerink Partners reduced their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company dropped their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of “Hold” and an average price target of $20.50.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds have recently bought and sold shares of KROS. Hsbc Holdings PLC increased its holdings in Keros Therapeutics by 29.5% in the 2nd quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock valued at $761,000 after buying an additional 15,940 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Keros Therapeutics during the 2nd quarter worth approximately $15,091,483,000. Empowered Funds LLC acquired a new stake in shares of Keros Therapeutics during the 2nd quarter worth approximately $1,521,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Keros Therapeutics during the 2nd quarter worth approximately $538,000. Finally, Bank of America Corp DE bought a new position in Keros Therapeutics in the second quarter valued at approximately $334,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.